Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysis.

Autor:	Karakizlis H; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany., Nahrgang C; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany., Strecker K; AID GmbH, Ebinger Straße 4, Strassberg 72479, Germany., Chen J; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany., Aly M; Transplantation Immunology, Institute of Immunology, University Hospital Heidelberg, Im Neuenheimer Feld 305, Heidelberg 69120, Germany.; Nephrology Unit, Internal Medicine Department, Assiut University, Governorate 71515, Assiut, Egypt., Slanina H; Institute of Medical Virology, Justus-Liebig-University Giessen, Schubertstraße 81, Giessen 35392, Germany., Schüttler CG; Institute of Medical Virology, Justus-Liebig-University Giessen, Schubertstraße 81, Giessen 35392, Germany., Esso I; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany., Wolter M; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany., Todorova D; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany., Jessen S; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany., Adamik A; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany., Ronco C; Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza, San Bortolo Hospital, Via Rodolfi, Vicenza 37-36100, Italy.; Department of Medicine (DIMED), Università di Padova, Via Giustiniani, Padua 2-35128, Italy., Seeger W; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany.; Member of the German Center for Lung Research (DZL), Universities of Giessen and Marburg Lung Center (UGMLC), Klinikstraße 33, Giessen 35392, Germany.; Department of Lung Development and Remodeling, Max Planck Institute for Heart and Lung Research, Ludwigstraße 43, Bad Nauheim 61231, Germany., Weimer R; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany., Sester M; Department of Transplant and Infection Immunology, Saarland University, Kirrberger Straße, Homburg 66421, Germany., Birk HW; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany., Husain-Syed F; Department of Internal Medicine II, University Hospital Giessen and Marburg, Justus-Liebig-University Giessen, Klinikstraße 33, Giessen 35392, Germany.; Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute of Vicenza, San Bortolo Hospital, Via Rodolfi, Vicenza 37-36100, Italy.
Jazyk:	angličtina
Zdroj:	Data in brief [Data Brief] 2022 May 16; Vol. 42, pp. 108271. Date of Electronic Publication: 2022 May 16 (Print Publication: 2022).
DOI:	10.1016/j.dib.2022.108271
Abstrakt:	Compared with the general population, patients receiving maintenance dialysis are at increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19). Currently, data on severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-specific immunity post-vaccination in patients on maintenance dialysis are scarce given that the effectiveness of the vaccines has not been explicitly tested in this population due to their common exclusion from SARS-CoV-2 vaccination trials. We herein present data of the specific cellular (interferon-γ and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay) at 4 weeks and 6 weeks following a single dose or a complete homologous dual dose SARS-CoV-2 vaccine regimen in 60 adult patients on maintenance dialysis (six with a history of COVID-19). The data was produced in a framework of a project focused on a) quantifying the immune response after full vaccination, b) evaluating the short-term durability of immune response, and c) examining the reactogenicity of SARS-CoV-2 vaccine regimens in patients on maintenance dialysis. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kevin Strecker is employee of AID/GenID, the manufacturer of the ELISpot assay. None of the other authors declare any competing interests. (© 2022 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu